22 October 2025 Just weeks into his tenure, USPTO director John Squires is blitzing US patent policy by taking control of how ...

Speakers from Greenberg Traurig, Verdiva Bio, Halozyme, and Metsera discuss the implications of the USPTO’s 2024 §112 ...

Dirk Buehler, Maiwald, discusses how the “try and see” standard is applied before the EPO and its relevance in pharma and ...

Amanda Simons, J A Kemp, explains how clinical research affects patentability in Europe and how clinical data can be used to ...

As Edwards secures another win against its rival, LSIPR talks to Siddharth Kusumakar—partner at Powell Gilbert and counsel for the winning party. Already registered? If you don't have a login or your ...

Latest News & FeaturesWith its landmark ruling, the court has delivered guidance for patentees and litigants— including three takeaways for counsel and rights holders, explain Tobias Wuttke and Axel ...

WATCH: Behind the scenes of big ticket litigation — lessons from the courts ...

The firm’s new hire is known for advising Boston’s biotech, pharmaceutical and chemical companies on patent strategies and ...

Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising ...

The proponents of a petition denied by the Supreme Court said it addressed a conflict that was significant “not just for the ...

28 November 2025 With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis ...

Biopharma company and two others have taken action against numerous defendants over proposed generic versions of Livmarli, Mirum’s core revenue driver. If you don't have a login or your access has ...